BLOG

knowledge

Company News

Industry News

2026.05.25

High-Quality Inner Bag Polyethylene Gloves for Hygienic, Safe, and Efficient Disposable Hand Protection Solutions

quality inner bag polyethylene gloves company provides hygienic disposable gloves for food, medical, and industrial use.

High-Quality Inner Bag Polyethylene Gloves for Hygienic, Safe, and Efficient Disposable Hand Protection Solutions

2025.05.20

Innovative medical consumables related services

In the third week of February 2025, the pharmaceutical and biological sector will continue its structural differentiation trend. The pharmaceutical and biological index rose 1.88% for the whole week, outperforming the Shanghai and Shenzhen 300 and Shanghai Composite Index, ranking 9th in terms of industry gains and losses. In the segmented field, medical R&D outsourcing led the way with an increase of 11.3%, while offline pharmacies fell by 3.06%, becoming the weakest performing sub industry. In terms of sector valuation, the current PE (TTM) is 26 times, still in the low range of nearly a decade. Market funds continue to gather towards hard technologies such as innovative drugs and AI healthcare, and the positive signals released by policies further strengthen the expectation of a bottoming out in the industry. Despite the broad prospects of AI healthcare, its development still faces challenges such as data compliance and long clinical validation cycles. The current market tends to focus on midstream platform companies that integrate algorithms, data, and clinical resources for "AI+healthcare", which can quickly achieve technology migration. At the same time, the synergistic effect between emerging technologies such as stem cell therapy and gene editing and AI is gradually emerging, which may become an important track for industrial competition in the next stage. It is worth noting that the balance between technological iteration speed and regulatory adaptability will become a key variable determining the pace of industry growth.

Innovative medical consumables related services

2025.04.15

Accelerating the implementation of medical application scenarios

In the third week of February 2025, the pharmaceutical and biological sector will continue its structural differentiation trend. The pharmaceutical and biological index rose 1.88% for the whole week, outperforming the Shanghai and Shenzhen 300 and Shanghai Composite Index, ranking 9th in terms of industry gains and losses. In the segmented field, medical R&D outsourcing led the way with an increase of 11.3%, while offline pharmacies fell by 3.06%, becoming the weakest performing sub industry. In terms of sector valuation, the current PE (TTM) is 26 times, still in the low range of nearly a decade. Market funds continue to gather towards hard technologies such as innovative drugs and AI healthcare, and the positive signals released by policies further strengthen the expectation of a bottoming out in the industry. Despite the broad prospects of AI healthcare, its development still faces challenges such as data compliance and long clinical validation cycles. The current market tends to focus on midstream platform companies that integrate algorithms, data, and clinical resources for "AI+healthcare", which can quickly achieve technology migration. At the same time, the synergistic effect between emerging technologies such as stem cell therapy and gene editing and AI is gradually emerging, which may become an important track for industrial competition in the next stage. It is worth noting that the balance between technological iteration speed and regulatory adaptability will become a key variable determining the pace of industry growth.

Accelerating the implementation of medical application scenarios

2025.03.01

Latest policies in the pharmaceutical industry

In the third week of February 2025, the pharmaceutical and biological sector will continue its structural differentiation trend. The pharmaceutical and biological index rose 1.88% for the whole week, outperforming the Shanghai and Shenzhen 300 and Shanghai Composite Index, ranking 9th in terms of industry gains and losses. In the segmented field, medical R&D outsourcing led the way with an increase of 11.3%, while offline pharmacies fell by 3.06%, becoming the weakest performing sub industry. In terms of sector valuation, the current PE (TTM) is 26 times, still in the low range of nearly a decade. Market funds continue to gather towards hard technologies such as innovative drugs and AI healthcare, and the positive signals released by policies further strengthen the expectation of a bottoming out in the industry. Despite the broad prospects of AI healthcare, its development still faces challenges such as data compliance and long clinical validation cycles. The current market tends to focus on midstream platform companies that integrate algorithms, data, and clinical resources for "AI+healthcare", which can quickly achieve technology migration. At the same time, the synergistic effect between emerging technologies such as stem cell therapy and gene editing and AI is gradually emerging, which may become an important track for industrial competition in the next stage. It is worth noting that the balance between technological iteration speed and regulatory adaptability will become a key variable determining the pace of industry growth.

Latest policies in the pharmaceutical industry
< 1...35363738 >
JINGJIN
Facebook Linkedin Twitter Tumblr Pinterest

Contact Us

Tel/WhatsApp:

+86 180 1853 1850

E-mail:

info@jingjingroup.com

Add:

Room 801, building 3,| No.518 Xinzhuan Road | Songjiang | Shanghai | 201612.China

language

Message

Submit
%{tishi_zhanwei}%

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

www.300.cn

JINGJIN GROUP

JINGJIN

Online Consultation

If you are interested in our products, please leave a message here and we will get back to you as soon as possible.

Submit